Free Account Opening + AMC Free Demat
Loading...

Aarti Drugs Buyback 2024 vs Ladderup Finance Buyback 2024

Comparision between Aarti Drugs Buyback 2024 and Ladderup Finance Buyback 2024.

Buyback Details

Aarti Drugs Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while Ladderup Finance Buyback 2024 is a Tender Offer proposed to list at BSE.

  Aarti Drugs Ltd. Ladderup Finance Ltd.
Logo Aarti Drugs Buyback 2024 Logo Ladderup Finance Buyback 2024 Logo
Type of Buyback Tender Offer Tender Offer
Listing At BSE, NSE BSE
Face Value ₹10 per share ₹10 per share
Buyback Price ₹900 per share ₹44 per share
Issue Size 6,65,000 shares 25,00,000 shares
Issue Size (Amount) ₹59.85 Crores ₹11.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders9 Equity Shares out of every 706 Fully paid-up Equity Shares held on the Record Date.99,750
General Category for all other Eligible Shareholders5 Equity Shares out of every 744 Fully paid-up Equity Shares held on the Record Date.5,65,250
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders265 Equity Shares out of every 288 Fully paid-up Equity Shares held on the Record Date.3,75,000
General Category for all other Eligible Shareholders177 Equity Shares out of every 428 Fully paid-up Equity Shares held on the Record Date.21,25,000
Registrar Link Intime India Private Ltd Link Intime India Private Ltd
Lead Managers Inga Ventures Pvt Ltd Mark Corporate Advisors Private Limited
Necessity of the buyback

The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company’s management strives to increase equity shareholder's value and the Buyback would result in amongst other things:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares;
  2. The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by a reduction in the equity base, thereby leading to a long-term increase in shareholders’ value;
  3. The Buyback gives an option to the shareholders holding Equity Shares of the Company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment; and
  4. The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public shareholders, who would be classified as Small Shareholders.

The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company's management strives to increase the value of equity shareholders.
After considering several factors and benefits to the shareholders holding Equity Shares of the Company, the Board decided to approve Buyback of up to 25,00,000 (Twenty Five Lakhs) Equity Shares of face value of 10 (Rupees Ten) each for 44/- (Rupees Forty Four only) per Equity Share for an aggregate amount not exceeding 11,00,00,000 (Rupees Eleven Crores Only) excluding the Transaction Costs, for distributing cash to the eligible shareholders. The Buyback is being undertaken, inter alia, for the following
reasons:
i) The Buyback will help the Company to return surplus funds to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby enhancing the overall return to shareholders;
ii) The Buyback will help the Company to optimise the capital structure;
iii) The Buyback, which is being implemented through the tender offer route as prescribed under the SEBI Buyback Regulations, would involve the allocation of several Equity Shares as per their entitlement or 15% of the number of Equity Shares to be bought back, whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who get classified as "small shareholder" as per Regulation 2(1)(n) of the SEBI Buyback Regulations. After accepting the equity shares tendered based on entitlement, equity shares left to be bought back, if any in one category shall first be accepted, in proportion to the equity shares tendered over and above their entitlement in the offer by equity shareholders in that category and thereafter from equity shareholders who have tendered over and above their entitlement in other category.
iv) The Buyback may help in improving financial ratios like earning per share, return on capital employed and return on equity, by reduction in the equity base, thereby leading to long term increase in shareholders' value; and
v) The Buyback gives an option to the shareholders holding Equity Shares of the Company. They can choose to participate and receive cash instead of Equity Shares to be accepted under the Buyback offer, or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post-buyback offer, without additional investment.

Buyback Timetable

Aarti Drugs Buyback 2024 and Ladderup Finance Buyback 2024 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Aarti Drugs Buyback 2024 Buyback record date is Sep 05, 2024. Ladderup Finance Buyback 2024 Buyback record date is Sep 06, 2024.

  Aarti Drugs Ltd. Ladderup Finance Ltd.
Record Date Sep 05, 2024 Sep 06, 2024
Offer Open Date Sep 11, 2024 Sep 11, 2024
Offer Closure Date Sep 19, 2024 Sep 19, 2024
Last date for receipt of tender forms Sep 19, 2024 Sep 18, 2024
Finalisation of buyback Sep 25, 2024 Sep 24, 2024
Last Date for settlment of bids Sep 26, 2024 Sep 25, 2024
Last Date for extinguishment of shares Oct 08, 2024 Oct 07, 2024

Financial Details and Other Relevent Information

Comparison of Aarti Drugs Buyback 2024 and Ladderup Finance Buyback 2024 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

  Aarti Drugs Ltd. Ladderup Finance Ltd.
Financial

Aarti Drugs Ltd. Financial Information (Restated Consolidated)

Aarti Drugs Ltd.'s revenue decreased by -7% and profit after tax (PAT) rose by 3% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 202231 Mar 2021
Assets2,421.42,207.961,766.01
Revenue2,532.612,718.252,499.962,159.31
Profit After Tax171.59166.36205280.4
Net Worth1,262.071,173.691,016.62
Amount in ₹ Crore

Ladderup Finance Ltd. Financial Information (Restated Consolidated)

Ladderup Finance Ltd.'s revenue increased by 13% and profit after tax (PAT) dropped by -200% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets99.6779.878.86
Revenue12.6211.1811.69
Profit After Tax-3.93-1.313.65
Net Worth68.0164.3865.66
Total Borrowing11.941.72.08
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 563.95 500.05 529.89
Jun-2024 538.90 450.20 507.91
May-2024 508.85 453.60 483.92

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Aug-2024 49.50 40.10 43.38
Jul-2024 51.50 36.04 41.52
Jun-2024 45.00 33.00 37.88
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 563.20 500.00 530.05
Jun-2024 538.95 451.05 508.13
May-2024 508.95 456.00 484.25

Comments

Add a public comment...